Overview

Safety, Tolerability, PK, and PD of LIM-0705 in Subjects With Impaired Glucose Tolerance or Abnormal HOMA-IR

Status:
Unknown status
Trial end date:
2011-08-01
Target enrollment:
Participant gender:
Summary
Preliminary research suggests that LIM-0705 improves insulin sensitivity with neutral effects on weight in obese and diabetic rodent models. Results from a Phase 1b clinical study, conducted in healthy volunteers, indicate that LIM-0705 and a major metabolite may be potential insulin sensitizers by OGTT.
Phase:
Phase 2
Details
Lead Sponsor:
Limerick BioPharma